Ortho Clinical Diagnostics

Ortho Clinical Diagnostics
Private
Industry
Founded Linden, New Jersey, United States
(1937 (1937))
Headquarters 1001 US-202, Raritan, New Jersey, United States
Area served
 Worldwide
Key people
Number of employees
 1,001 to 5,000 (2014)[1]
Website orthoclinical.com

Ortho Clinical Diagnostics is a company that makes in vitro diagnostics products and diagnostic equipment for blood testing. It was created following Johnson and Johnson's acquisition of Eastman Kodak's Clinical Diagnostics Division in 1994 (to form Johnson & Johnson Clinical Diagnostics), which was then merged with Ortho Diagnostic Systems in 1997. Their corporate offices are in Raritan, New Jersey, while their main research and manufacturing facilities are in Rochester, New York. The business has two major segments: Transfusion Medicine which is involved in screening human blood, and Clinical Laboratories, which does a variety of chemical and immunodiagnostic testing.

In 2014, The Carlyle Group purchased the company from Johnson & Johnson for $4.15 billion. Ortho Clinical Diagnostics now operates as an independent company.[2][3]

Ortho Clinical Diagnostics (Ortho) unveiled its newly expanded executive leadership team following the acquisition of the company by The Carlyle Group (NASDAQ: CG) from Johnson & Johnson. In his first act as OCD Chairman and Chief Executive Officer, Dr. Martin D. Madaus announced[4] key appointments in finance, operations, legal and commercial to advance strategic sectors of the In Vitro Diagnostics (IVD) business.

History

1937: Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson.

1944: Dr. Philip Levine, a pioneer in the field of hematology, joins Ortho Products to continue his research into the mechanics of the Rh system in human blood.[5]

1994: Ortho Clinical Diagnostics was created following Johnson and Johnson's acquisition of Eastman Kodak's Clinical Diagnostics Division in 1994 to form Johnson & Johnson Clinical Diagnostics.

1997: Ortho Clinical Diagnostics merged with Ortho Diagnostic Systems.

2001: Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests. [6] [7]

2006: Ortho Clinical Diagnostics launches the first FDA-licensed test to screen blood donations for exposure to Chagas disease.[8]

2014: The company was sold to The Carlyle Group for $4.15 billion. [9]

References

  1. ↑ "Ortho Clinical Diagnostics-LinkedIn".
  2. ↑ Daneman, Matthew (16 January 2014). "Carlyle to buy Ortho-Clinical for $4.15 billion". Democrat and Chronicle. Retrieved 23 March 2014.
  3. ↑ https://www.carlyle.com/news-room/news-release-archive/carlyle-group-completes-acquisition-ortho-clinical-diagnostics-inc-oc
  4. ↑ http://www.businesswire.com/news/home/20150427006258/en/Ortho-Clinical-Diagnostics-Appoints-Industry-Veterans-Board
  5. ↑ http://www.nytimes.com/1987/10/20/obituaries/dr-philip-levine-87-is-dead-discovered-blood-s-rh-factor.html
  6. ↑ http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm088991.htm
  7. ↑ http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=13728
  8. ↑ http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5607a2.htm
  9. ↑ http://dealbook.nytimes.com/2014/01/16/carlyle-buys-johnson-johnson-testing-division-for-4-15-billion/?_r=0

External links

This article is issued from Wikipedia - version of the Tuesday, April 12, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.